Work

LILRB2 blockade modulates macrophages and other myeloid cells in cancer immunotherapy

Year: 2026
Type: article
Abstract: Leukocyte immunoglobulin-like receptor B2 (LILRB2), also known as immunoglobulin-like transcript 4 (ILT4), is an inhibitory receptor expressed in monocytes, macrophages, dendritic cells and neutrophils and, in selected cancers, malignant cells. The abundance and presentation of HLA class I molecules and other tumor-associated ligands help determine where this inhibitory pathway operates. Antagonistic antibodies have entered clinical development alone and with PD-(L)1 blockade. Across independent human monocyte-derived macrophage systems, antagonism shifts differentiation, increases inflammatory cytokine output and improves support for T-cell activation or tumor-cell killing. Tumor explants and humanized or transgenic mouse models show related changes in mixed myeloid populations. Dendritic cells, suppressive myeloid cells and malignant cells also alter immunity and tumor control through LILRB2-dependent or parallel routes. Transcriptomic and proteomic studies associate this macrophage response with lipid handling, endocytic transport and antigen presentation. Phase I studies of MK-4830 and IO-108 show sustained peripheral target occupancy and preliminary activity, and randomized MK-4830 studies provide initial comparative estimates for pembrolizumab-based combinations. LILRB2 is therefore best viewed as a broader myeloid-modulating target, with macrophage activity as a prominent component whose contribution to treatment response may differ among tumors. Patient selection and evaluation of PD-(L)1 combinations should incorporate tumor ligand availability, receptor-bearing cell composition and paired intratumoral measurements of target engagement, macrophage function and local T-cell activity.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $1,690
OpenAlex ID: W7237180994
FWCI:
Cites:
Cited by:
Related to: 10